14 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2036. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2036
Next term end
7
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2036 · High confidence
Also notable
Ends Mar 2040 · High confidence
Also notable
Ends Mar 2040 · High confidence
Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer
US 11,517,589
Cited by 4 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036.
Engineered Phagocytic Receptor Compositions and Methods of Use Thereof
US 11,026,973
The most cited patent in this portfolio, cited by 11 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Therapeutic Cell Compositions and Methods of Manufacturing and Use Thereof
US 10,980,836
The most cited patent in this portfolio, cited by 11 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 13, 2026The maintenance fee for Methods and Compositions for Genomic Integration (US 11,672,874) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
- 2 fees due Sep 5, 2027
- 1 fee due Oct 2, 2027The maintenance fee for Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof (US 11,944,680) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
What they patent
The 5 largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions for Genomic Integration | 3 in force | to Jul 2043 |
| Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer | 3 in force | to Feb 2036 |
| Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof | 2 in force | to Nov 2041 |
| Therapeutic Cell Compositions and Methods of Manufacturing and Use Thereof | 2 in force | to Nov 2040 |
| Engineered Phagocytic Receptor Compositions and Methods of Use Thereof | 2 in force | to Mar 2040 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,517,589 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 11,918,604 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 11,918,605 | Chimeric Antigen Receptor Dendritic Cell (CAR-DC) for Treatment of Cancer In force · High confidence | In force | High confidence | |
| US 10,980,836 | Therapeutic Cell Compositions and Methods of Manufacturing and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,013,764 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 11,026,973 | Engineered Phagocytic Receptor Compositions and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 12,599,678 | Methods and Compositions for Genomic Integration In force · Low confidence | In force | Low confidence | |
| US 11,672,874 | Methods and Compositions for Genomic Integration In force · Low confidence | In force | Low confidence | |
| US 12,252,545 | Therapeutic Cell Compositions and Methods of Manufacturing and Use Thereof In force · High confidence | In force | High confidence | |
| US 11,628,218 | Engineered Chimeric Fusion Protein Compositions and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 14: 18 applications pending · 1 application abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.